Fig. 5: Early ctDNA changes after one week of trastuzumab monotherapy predict outcomes. | Nature Communications

Fig. 5: Early ctDNA changes after one week of trastuzumab monotherapy predict outcomes.

From: Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

Fig. 5

A Initial therapeutic strategy on this trial included trastuzumab monotherapy which was followed by the complete regimen being given 7 days later. Tumor fraction at time of trastuzumab monotherapy and one week post are shown. Cases with % ctDNA decrease > median are in blue, and those with % ctDNA decrease <median or ctDNA increase are in red (n = 11 each). Cases with tumor fraction <0.05 (horizontal dashed line) were excluded from the analysis. B Cases with higher drop in ctDNA (blue) after one week of trastuzumab monotherapy have trend towards improved PFS. P-value was calculated using two-tailed log rank test B.

Back to article page